Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment

2011 ◽  
pp. n/a-n/a ◽  
Author(s):  
Gerald T. Ankley ◽  
Richard S. Bennett ◽  
Russell J. Erickson ◽  
Dale J. Hoff ◽  
Michael W. Hornung ◽  
...  
2010 ◽  
Vol 29 (3) ◽  
pp. 730-741 ◽  
Author(s):  
Gerald T. Ankley ◽  
Richard S. Bennett ◽  
Russell J. Erickson ◽  
Dale J. Hoff ◽  
Michael W. Hornung ◽  
...  

Author(s):  
R. Julian Preston ◽  
Werner Rühm ◽  
Edouard I. Azzam ◽  
John D. Boice ◽  
Simon Bouffler ◽  
...  

2017 ◽  
Vol 158 (2) ◽  
pp. 252-262 ◽  
Author(s):  
Erica K. Brockmeier ◽  
Geoff Hodges ◽  
Thomas H. Hutchinson ◽  
Emma Butler ◽  
Markus Hecker ◽  
...  

2020 ◽  
pp. 1-24
Author(s):  
Sabina Halappanavar ◽  
James D. Ede ◽  
Indrani Mahapatra ◽  
Harald F. Krug ◽  
Eileen D. Kuempel ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Mounika Gayathri Tirumala ◽  
Pratibha Anchi ◽  
Susmitha Raja ◽  
Mahesh Rachamalla ◽  
Chandraiah Godugu

Nanotoxicology is an emerging field employed in the assessment of unintentional hazardous effects produced by nanoparticles (NPs) impacting human health and the environment. The nanotoxicity affects the range between induction of cellular stress and cytotoxicity. The reasons so far reported for these toxicological effects are due to their variable sizes with high surface areas, shape, charge, and physicochemical properties, which upon interaction with the biological components may influence their functioning and result in adverse outcomes (AO). Thus, understanding the risk produced by these materials now is an important safety concern for the development of nanotechnology and nanomedicine. Since the time nanotoxicology has evolved, the methods employed have been majorly relied on in vitro cell-based evaluations, while these simple methods may not predict the complexity involved in preclinical and clinical conditions concerning pharmacokinetics, organ toxicity, and toxicities evidenced through multiple cellular levels. The safety profiles of nanoscale nanomaterials and nanoformulations in the delivery of drugs and therapeutic applications are of considerable concern. In addition, the safety assessment for new nanomedicine formulas lacks regulatory standards. Though the in vivo studies are greatly needed, the end parameters used for risk assessment are not predicting the possible toxic effects produced by various nanoformulations. On the other side, due to increased restrictions on animal usage and demand for the need for high-throughput assays, there is a need for developing and exploring novel methods to evaluate NPs safety concerns. The progress made in molecular biology and the availability of several modern techniques may offer novel and innovative methods to evaluate the toxicological behavior of different NPs by using single cells, cell population, and whole organisms. This review highlights the recent novel methods developed for the evaluation of the safety impacts of NPs and attempts to solve the problems that come with risk assessment. The relevance of investigating adverse outcome pathways (AOPs) in nanotoxicology has been stressed in particular.


Sign in / Sign up

Export Citation Format

Share Document